For the quarter ending 2025-09-30, QLGN has $43,470,364 in assets. $38,777,166 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Cash and cash equivalents | 38,777,166 | 331,601 | 30,210 | |
| Prepaid expenses and other current assets | 343,091 | 316,576 | 565,765 | |
| Other current assets | - | - | 20,000 | |
| Short-term notes receivable, net of allowance for credit losses of 261,000 at september 30, 2025 and 360,000 at december 31, 2024 | 4,348,107 | 3,312,496 | 2,229,563 | |
| Total current assets | 43,468,364 | 3,960,673 | 2,845,538 | |
| Other assets | 2,000 | 2,000 | 2,000 | |
| Total assets | 43,470,364 | 3,962,673 | 2,847,538 | |
| Accounts payable | 1,282,224 | 1,404,611 | 1,530,735 | |
| Accrued expenses and other current liabilities | 41,896 | 379,633 | 210,104 | |
| Warrant liabilities | 362,323 | 213,976 | 229,950 | |
| Convertible debt | 339,736 | 142,069 | - | |
| Promissory notes | 2,897,107 | 3,474,667 | 843,615 | |
| Total current liabilities | 4,923,286 | 5,614,956 | 2,814,404 | |
| Preferred stock, 0.001 par value 15,000,000 shares authorized 45,044 and 6,256 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 36,100,334 | 2,790,007 | 2,823,094 | |
| Common stock, 0.001 par value 225,000,000 shares authorized 3,056,822 and 736,431 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 67,734 | 66,213 | 66,203 | |
| Additional paid-in capital | 131,809,991 | 122,884,659 | 122,851,582 | |
| Accumulated deficit | -129,430,981 | -127,393,162 | -125,707,745 | |
| Total stockholders equity | - | - | 33,134 | |
| Total stockholders equity (deficit) | 38,547,078 | -1,652,283 | - | |
| Total liabilities & stockholders equity (deficit) | 43,470,364 | 3,962,673 | 2,847,538 | |
Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. (QLGN)